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PURPOSE. To assess the effect of ocriplasmin on visual function response (VFR) measured using
visual acuity (VA) and vision-related quality of life, and to quantify the association between
release of vitreomacular adhesion (VMA) at day 28 and VFR.
METHODS. Prespecified analysis of secondary endpoints from a randomized controlled trial. Of
220 participants with symptomatic VMA/vitreomacular traction (VMT), including VMT
associated with a macular hole up to 400 lm, 146 received a single intravitreal injection of
125 lg ocriplasmin and 74 a sham injection. Based on principal components analysis results, a
VFR was defined as either a VA improvement of ‡2 lines or an improvement exceeding the
minimal clinically important difference (MCID) in the composite or the mental health
subscale scores of the Visual Function Questionnaire (VFQ-25). The MCID was estimated
using the standard error of measurement approach. The main outcome measure was the VFR
at month 6, with further assessments at months 12 and 24.
RESULTS. The MCID was estimated at 3.71 points for the VFQ-25 composite score and 10.71 for
the VFQ-25 mental health subscale score. A VFR occurred in 51.0% of ocriplasmin versus
23.3% of sham participants (P ¼ 0.0001). The VFR was maintained through months 12 and
24: 53.1% and 50.3% in ocriplasmin versus 21.9% and 20.5% in sham participants, respectively
(P < 0.0001). Resolution of VMA at day 28 significantly increased the odds of a VFR at each
assessment period.
CONCLUSIONS. Treatment with ocriplasmin compared with sham resulted in a significant
improvement in VFR. The 6-month treatment effect was sustained at months 12 and 24.
Keywords: macular hole, minimal clinically important difference, ocriplasmin, principal
components analysis, patient-reported outcomes, sham, symptomatic vitreomacular adhe-
sion/vitreomacular traction, VFQ-25
Vitreomacular traction (VMT), also referred to as symptom-atic vitreomacular adhesion (VMA), is characterized by an
incomplete posterior vitreous detachment with persisting VMA
that causes distortion of the foveal anatomy. It can be associated
with variable loss of visual function.1,2 The traction can also
progress to cause a full-thickness macular hole. Visual
symptoms include metamorphopsia, reduced visual acuity
(VA), blurred vision, micropsia, scotoma, and difficulties with
daily vision-related tasks.1,3,4 Treatment depends largely on the
cause, but options include observation, pars plana vitrectomy
(PPV), and pharmacologic vitreolysis.5–7 Observation is typi-
cally advocated for stable mild VMT that does not justify the
risks of surgery, or in the expectation that some cases will
resolve spontaneously.1,4–6 Vitrectomy is the most common
treatment for clinically significant VMT and most cases with
macular hole; however, PPV carries the risks of intra- and
postoperative complications with modest visual acuity im-
provements in cases of VMT.1,7,8
Ocriplasmin was approved in the United States in 2012 and
Europe in 2013, based on the results of the two MIVI-TRUST
phase 3 clinical trials.9 In both regions the indication is VMT,
including VMT associated with a macular hole up to 400 lm in
apical diameter. In the United States, these two related
indications (VMT and macular hole) are grouped together
under the term, ‘‘symptomatic.’’
Subgroup analyses determined that ocriplasmin is most
effective for focal VMA (1500 lm), and in the absence of
epiretinal membrane (ERM).10,11 More recently, the Ocriplas-
min for Treatment for Symptomatic Vitreomacular Adhesion
Including Macular Hole study (OASIS; clinicaltrials.gov identi-
fier: NCT01429441) reported improved efficacy of ocriplasmin
using refined case selection that was based on the baseline
characteristics predictive of resolution.12,13 The OASIS study
had longer follow-up than MIVI-TRUST (24 vs. 6 months),
higher-resolution optical coherence tomography (OCT), and
more visual function tests.12
VMT is often discovered in association with decreased VA;
however, symptoms, most commonly metamorphopsia, can
occur despite good or relatively normal acuity.4 Metamorphop-
sia can be very troublesome for patients, and can markedly
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impair reading and face recognition.14,15 Metamorphopsia is
often overlooked, perhaps due to overreliance on OCT
imaging, which often correlates poorly with visual func-
tion.14,16–19 Likewise, VA can correlate poorly with metamor-
phopsia and visual dysfunction in patients with VMT and
macular hole.20–22 Further, quantitative evaluation of meta-
morphopsia is often difficult, and is not yet part of routine
clinical practice.14,16,23
Given the limitations of VA and OCT in patients with VMT,
there is a need to find a more patient-centered outcome
measure; one that incorporates the complexity of visual
dysfunction secondary to VMT, and the impact thereof. With
this in mind, we previously studied visual function data
obtained during the MIVI-TRUST trials to establish a clinically
meaningful definition of visual function response (VFR). Based
on a principal components analysis (PCA), a technique to
reduce the dimensionality of multivariate data while preserving
as much of the relevant information as possible,24 VFR was
defined as either a VA improvement of ‡2 lines; an
improvement in the composite score of the National Eye
Institute Visual Function Questionnaire (VFQ-25) exceeding
the minimal clinically important difference (MCID), estimated
using the standard error of measurement approach; or an
improvement in the VFQ-25 driving subscale score exceeding
the MCID. Using this established methodology, we showed that
ocriplasmin produced a clinically meaningful visual function
benefit over placebo.17
The OASIS study presents the opportunity to repeat our
previous analysis in a study group that is more generalizable to
current care, as OASIS excluded eyes with ERM and there was a
sham rather than placebo-injection control. The OASIS study
also has longer follow-up than MIVI-TRUST. We aimed to test
the hypothesis that ocriplasmin is more likely to produce a VFR
than sham, and that short-term VMA release is associated with
longer-term visual function benefit. We tested our hypotheses
using a prespecified analysis of visual function data obtained
during the OASIS study, looking specifically at VA and the VFQ-
25.
METHODS
Participants
We analyzed data from the previously reported OASIS trial.12
Briefly, OASIS was a phase 3b, randomized, sham-controlled,
double-masked, multicenter clinical trial designed to provide
longer-term outcomes on the efficacy and safety profile of
ocriplasmin, with refined case selection based on the MIVI-
TRUST subgroup analyses.10,11 OASIS enrolled 220 participants
(146 ocriplasmin, 74 sham) across 25 US sites. All participants
had a clinical diagnosis of VMT defined as the presence of VMA
that was related to decreased visual function. All eyes had
either VMT alone, or VMT associated with a full-thickness
macular hole. Although ERM was an exclusion criterion, 23.0%
of eyes were diagnosed with ERM by the central reading center
(CRC) after enrollment, in conflict with the initial assessment
by the recruiting clinical investigator. Participants received a
single intravitreal injection of 125 lg of ocriplasmin or sham
injection, and were assessed over 24 months. The primary
efficacy endpoint was the proportion of participants with
pharmacologic VMA resolution at day 28. If the underlying
condition had not resolved by day 28, or if there was a
deterioration before day 28, such as a new macular hole or
worsening of best-corrected VA (BCVA), the clinical investiga-
tor could advise PPV (data on file).
OASIS was conducted in accordance with the Declaration of
Helsinki. Institutional review board approval was obtained at
each site, and participants provided written informed consent
before enrollment.
Assessment of Visual Function and VFR Definition
BCVA was measured at each study visit using an Early
Treatment Diabetic Retinopathy Study (ETDRS) chart.25
Because metamorphopsia, micropsia, and other symptoms of
VMA are not quantifiable on ETDRS charts, another measure
was needed to evaluate changes in vision-related function.3
Therefore, in addition to BCVA assessments, participants were
examined using a functional assessment of visual ability, the
VFQ-25.12 The VFQ-25 is a validated instrument designed to
examine the influence of eye conditions and interventions on a
patient’s day-to-day functioning and well-being. The 25-item
survey measures the patient’s subjective assessments of visual
function, and has been widely used in ophthalmologic
research.26,27 In OASIS, the survey was administered at
baseline and months 6, 12, and 24. The current VFR analysis
was protocol prespecified and explored the change in BCVA
and VFQ-25 scores from baseline to months 6, 12, and 24.
Following methods described in our previous analysis, we
conducted a responder analysis that classified each participant
as having a VFR, or not.17 First, PCA was used to determine the
variables that summarize the VFQ-25 responses best in two
dimensions.24 A PCA can reduce a multidimensional response
into a restricted set of responses, called Principal Components
(PCs), in an objective way while preserving as much of the
overall variability in the multidimensional response as possible
(see Supplementary Materials for details on PCA and its
[dis]advantages). Second, for each of these variables, a
threshold for meaningful response reflecting the MCID was
required.28 For BCVA, the MCID was defined as a 2-line or
larger change, which is believed to be a clinically important
change in people with better VA.29,30 In the absence of a
suitable anchor, a distribution-based metric, the standard error
of measurement, was used for the VFQ-25 scores.31 These
thresholds were determined by the best method available as
recommended by the Food and Drug Administration Guidance
on Patient-Reported Outcomes.32
Main Analyses
The primary analysis estimated the effect of treatment
(ocriplasmin versus sham) on the VFR measures at month 6
and was performed on all randomized participants, per the
intent-to-treat principle. Additional analyses explored the
following: (1) the effect of treatment on VFR at months 12
and 24; (2) the association between anatomic response (VMA
release versus persisting VMA defined as VMA resolution at day
28 versus no VMA resolution at day 28, respectively) and VFR
at the different time points; (3) the effect of treatment in
subgroups of participants with VMA release versus persisting
VMA (release of VMA did not consider whether or not a
macular hole was present); and (4) the effect of treatment on
VFR in subgroups defined by whether the participants had a
macular hole at baseline or not.
Statistical Methods
Missing data for BCVA were imputed using the last observation
carried forward (LOCF). LOCF is an often-used technique in
clinical trials to enable the use of all evidence. It does not
generate biases in the randomized comparison whenever we
can assume that the missingness is random.
VFQ-25 scores were computed on observed individual items
as per its scoring algorithm.33 The effect of treatment on VFR
(in the overall study population and in subgroups defined by
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anatomic response), and the associations between anatomic
response and VFR were estimated through logistic regression
models. The latter provided insight into correlations between
the anatomic response and the different VFR measures and
identified whether participants without anatomic response still
obtained a functional benefit. Odds ratios (ORs) reported the
measure of association between exposure (active treatment;
anatomic response) and outcome (VFR). The proportion of
participants with VFR by exposure group was provided as a
summary statistic. The likelihood ratio test was used to test
whether the ORs differed from 1. All tests were considered
significant if P < 0.05. All analyses were carried out using SAS
version 6.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Baseline Demographics
Demographics and baseline ocular characteristics were com-
parable between treatment groups. Differences in assessment
between investigator and CRC for the presence or absence of
VMA, macular hole (including diameter), and ERM led to the
enrollment of participants meeting exclusion criteria. Of 145
participants in the ocriplasmin group, 33.0% (48/145) required
a vitrectomy by month 24, versus 43.0% (32/73) in the sham
group. Overall, 74.0% (108/146) and 68.9% (51/74) of
participants randomized to ocriplasmin and sham, respectively,
completed the 2 years of follow-up.12 In the ocriplasmin and
sham groups, respectively, mean BCVA scores were 63.5 and
62.4 ETDRS letters, the VFQ-25 composite scores (VFQ-CS)
were 78.0 and 80.7 (for scores per VFQ-25 subscale, see
Supplementary Table S1).
VFR Definition
According to the PCA, the variables that best summarized the
VFQ-25 questionnaire information in two dimensions corre-
sponded to the VFQ-CS and the VFQ-25 mental health subscale
score (VFQ-MHS). The BCVA score showed weak correlations
with those two variables and was therefore considered to
provide complementary information. For the BCVA score, the
well-established threshold of an improvement of ‡2 VA lines
(10 letters) was used to distinguish response from nonre-
sponse. The MCID values obtained were 3.7 points for the
VFQ-CS, and 10.7 points for the VFQ-MHS. A PPV was
considered a rescue therapy, so participants who required a
PPV were classified as a visual function nonresponder. Overall
VFR was defined as an improvement exceeding the MCID
threshold in any of the three principal traits of visual function
identified from the PCA: BCVA, the VFQ-CS, or the VFQ-MHS.
Assessment of Treatment Effect
At month 6, 51.0% of ocriplasmin-treated participants had a
VFR, in that they improved in at least one of the three visual
function scores (VFQ-CS, VFQ-MHS, or BCVA score) versus
23.3% of sham-treated participants (OR 3.43, P ¼ 0.0001, v2
test) (Table 1).
VFR results assessed at months 12 and 24 were similar to
the month 6 analysis (Fig. 1). Treatment with ocriplasmin
versus sham showed a significant effect on VFR for the
individual visual function scores VFQ-CS, VFQ-MHS, and BCVA,
as well as for the composite overall VFR score (Supplementary
Table S2.1). Sensitivity analyses, in which participants who
underwent vitrectomy were not automatically classified as
visual function nonresponders, gave similar results to the
primary analysis for the overall VFR (Supplementary Table
S2.2).
Association Assessment
Participants who achieved a pharmacological VMA resolution
at day 28 showed significantly higher odds of overall VFR at
each time point (Fig. 2). Details per individual visual function
score over time are provided in Supplementary Table S3.
Subgroup Analyses
In the subgroup of participants with VMA release, no
significant differences were observed between ocriplasmin
and sham participants for any of the individual VFR scores, or
the combined, overall VFR (Fig. 3). In the persisting VMA
subgroup, a significantly higher proportion of responders was
observed in the ocriplasmin compared with the sham
participants for the overall VFR, VFQ-CS, and VFQ-MHS, but
not BCVA score (details are provided in Supplementary Table
S4).
In the subgroup of participants with no macular hole at
baseline, a significant treatment effect on the overall VFR was
found at month 6 (P < 0.0001), but not for the subgroup with
macular hole at baseline (P ¼ 0.297). Participants with no
macular hole at baseline seem to benefit more from the active
treatment. The overall treatment effect (across the total
population) mainly comes from the subgroup with no macular
hole (larger OR), and less from the subgroup with macular hole
at baseline (Table 2).
DISCUSSION
The VFR analysis demonstrated that half of the ocriplasmin-
treated participants had a VFR, compared with just under a
quarter of those receiving sham (51.0% vs. 23.3%; OR 3.43; P¼
0.0001). This treatment effect was maintained up to month 24.
TABLE 1. VFR at Month 6, by Treatment Group
Response
Variable
Ocriplasmin Sham
OR 95% CIn/N % n/N %
VFQ-CS 49/145 33.8 9/73 12.3 3.63 1.67–7.90
VFQ-MHS 41/145 28.3 9/73 12.3 2.80 1.28–6.15
BCVA score 42/144 29.2 12/73 16.4 2.09 1.02–4.28
Overall VFR 74/145 51.0 17/73 23.3 3.43 1.82–6.47
VFQ-CS ¼ responder with respect to VFQ-25 composite score
difference from baseline to month 6 (increase ‡ 3.7); VFQ-MHS ¼
responder with respect to VFQ-25 mental health subscale score
difference from baseline to month 6 (increase ‡10.7); BCVA score ¼
responder with respect to BCVA difference from baseline to month 6
(increase ‡2 lines); Overall VFR ¼ responder with respect to either
VFQ-CS or VFQ-MHS or BCVA score.
TABLE 2. VFR at Month 6, by Subgroups With and Without Macular
Hole at Baseline
Overall VFR
Ocriplasmin Sham
OR 95% CISubgroups n/N % n/N %
No macular hole
at baseline
61/95 64 13/47 28 4.69 2.18–10.08
Macular hole
at baseline
13/50 26 4/26 15 1.93 0.56–6.67
Overall VFR defined by the three VFR measures combined: VFQ-CS
or VFQ-MHS or BCVA score. In the subgroup with a macular hole at
baseline, the number of participants who achieved a closure at month
6 was 15 and 4 in the ocriplasmin and sham groups, respectively.
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In addition, pharmacological VMA resolution at day 28 was
significantly associated with higher VFR, out to 24 months.
Finally, the treatment effect at month 6 was significant in the
subgroup with no macular hole at baseline but not in the
subgroup with macular hole at baseline.
These results are in line with those we obtained using
similar methodology on the MIVI-TRUST dataset, although
OASIS found a greater magnitude of difference between the
ocriplasmin and control groups. For example, there was a
35.5% and 16.5% greater anatomic response compared with
the control group, for OASIS and MIVI-TRUST, respectively.9,12
This is most likely due to the patient eligibility criteria and the
absence of a volume effect from saline placebo injection used
in MIVI-TRUST (OASIS used a sham injection). Similarly, a larger
difference in VFR response was found in the current OASIS
analysis (27.7% difference favoring ocriplasmin over sham)
compared with the MIVI-TRUST study (20.9% difference
favoring ocriplasmin over placebo).17
From the output of the current PCA, the VFQ-25 mental
health subscale was retained as the second trait of visual
function. This contrasts with our MIVI-TRUST VFR report,
whereby the driving subscale of the VFQ-25 was identified as
important and complementary information of visual function
in symptomatic VMA/VMT patients.17 This is not totally
unexpected, because the OASIS study population differs
somewhat from the MIVI-TRUST population in terms of eligible
vision (BCVA of 20/32 or worse in study eye), exclusion criteria
(e.g., presence of ERM), or the study setting (United States
only). In addition, the proportion of participants with a
FIGURE 1. VFR at months 6, 12, and 24, by treatment group. Visual function responder, defined as a responder with respect to either VFQ-CS or
VFQ-MHS or BCVA score. N ¼ 73, sham; N ¼ 145, ocriplasmin.
FIGURE 2. Association between VMA resolution at day 28 and VFR over time. VMA release¼ Participant with VMA resolution at day 28. Persisting
VMA¼Participant without VMA resolution at day 28. VFR defined as a responder with respect to either VFQ-CS or VFQ-MHS or BCVA score. N¼67,
VMA release; N¼ 151, persisting VMA.
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macular hole or with VMA 1500 lm was higher compared
with MIVI-TRUST.9,12
Findings from the current OASIS VFR analysis are consistent
with reports that ocriplasmin produced greater BCVA and VFQ-
25 improvements than placebo at month 6, and that VMA
resolution at day 28 was associated with visual function
improvements.3,19 Gandorfer et al.19 reported a higher
proportion of eyes with a ‡2-line VA improvement (28.0%
vs. 17.1%) and a numerically better improvement in the VFQ-
25 composite score (3.4 vs. 0.7 units) comparing ocriplasmin
with placebo. With both ocriplasmin and placebo groups
combined, the proportion of eyes with a 2-line VA improve-
ment was 2-fold higher in participants with VMA release
compared with those with persisting VMA, with similar VFQ-
CS findings at month 6.19 Varma et al.3 likewise observed a
significant improvement in the VFQ-CS in ocriplasmin-treated
participants with VMA resolution versus those without.
Additionally, Varma et al.3 found that ocriplasmin-treated
participants with persisting VMA nonetheless gained a benefit,
with numerically greater improvement in the VFQ-CS com-
pared with placebo. They hypothesized that partial VMA
resolution may explain this benefit.3 Our findings lend support
to their hypothesis, as we found that treatment with
ocriplasmin resulted in significantly higher VFR than sham
despite persisting VMA (44.6% vs. 23.5%; OR 2.61; P¼ 0.008).
More recently, case studies reported improved VA and clinical
benefits despite only partial release of vitreomacular attach-
ments after ocriplasmin injection.18 In contrast to others’
work, the current analysis uses randomized evidence to assess
the effect of treatment on a combined VFR endpoint rather
than single functional outcomes such as BCVA or the VFQ-25
composite score.
Treatment may influence the closure of the macular hole,
and through this anatomic effect also lead to an improvement
of the VFR. In the subgroup with a macular hole at baseline,
more participants in the ocriplasmin group compared with the
sham group achieved macular hole closure and, therefore, had
a higher chance of being a visual function responder. Macular
hole closure can thus be considered as a mediator of the
treatment effect.
It could be expected that vitrectomy leads to VFR in some
participants. This was explored in our sensitivity analysis in
which participants who required a vitrectomy were not
automatically classified as a failure in terms of their VFR. This
sensitivity analysis confirmed higher VFR rates in both
treatment groups (Supplementary Table S2.2). However, as
the incidence of vitrectomy was higher for sham-treated
compared with ocriplasmin-treated participants, the additional
increase in VFR was larger in the sham group.
This analysis has several strengths. The randomized, double-
masked design of the OASIS trial suggests that the observed
differences may be causal and unbiased, the visual and
functional outcomes were collected rigorously within a clinical
trial, and the total sample size was sufficiently large to detect
meaningful clinical differences for most measures. All SD-OCT
assessments were determined by a masked CRC. Further, the
analysis was protocol prespecified, and used a scientifically
accepted method. The MCID for the VFQ-25 scores were
established using a data-driven technique and were in line with
published evidence.
Limitations of the analysis include the fact that subgroup
analyses based on posttreatment variables, such as VMA
resolution at day 28 postinjection, are descriptive, as each
subgroup represents a selection of participants that may
deviate from the randomized population, and may no longer
be equally represented across the two arms of the trial. Also, in
some subgroups, particularly those with released VMA, there
were few sham-injected participants, so results must be
interpreted cautiously.
This study focuses on the beneficial effects of ocriplasmin
and observes VFR in the OASIS treatment arms as a whole. It
does not consider the impact of any safety events on
individuals. The decision to use ocriplasmin is based on a
benefit-risk consideration, taking also the potential safety risks
into account. Adverse events observed in the trial are detailed
in the main OASIS report,12 and summarized in Supplementary
Table S5. The three most commonly reported adverse events in
the ocriplasmin group (study eye) were vitreous floaters,
photopsia, and vision blurred. Retinal breaks (defined as retinal
detachment and retinal tear) were more common in the
FIGURE 3. Effect of treatment on VFR at month 6, by VMA subgroup. VMA release¼ Participant with VMA resolution at day 28. Persisting VMA¼
Participant without VMA resolution at day 28. Visual function responder¼ Responder with respect to either VFQ-CS or VFQ-MHS or BCVA score.
Ocriplasmin: N ¼ 62 VMA release, N ¼ 83 persisting VMA; Sham: N¼ 5 VMA release, N ¼ 68 persisting VMA.
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control arm, most likely due to a higher rate of vitrectomy.
Serious adverse events (study eye) were comparable between
treatment groups; the most common serious adverse events
were macular hole and retinal detachment. Other adverse
events are reported in the OASIS study, and other reports in the
literature, including outer photoreceptor dysfunction, enlarge-
ment of the basal diameter of macular holes, and electrophys-
iology changes.12,34,35 Our study considers adverse events only
insofar as they influence the overall VFR.
PCA is a data reduction technique that simplifies complex
datasets. It aims to reveal the internal structure of a high-
dimensional dataspace in a way that best explains the variance
(or information) in the data. The advantage of our PCA was that
the PCs were determined using baseline data, in the form of
the VFQ-25 values. As such, the key dimension or internal
structure of visual functioning was established independent of
treatment. A possible disadvantage of PCA is that its typical
outputs (PCs) are rather abstract concepts and difficult to
associate with a clinical reality. In the PCA of the OASIS dataset,
we could replace the PCs by highly correlated original
variables (‘‘response measure’’) that are easier to understand
from a clinical point of view. The alternative approach would
entail an analysis of each of the questionnaire items separately,
correctly adjusted for multiple comparisons.
In conclusion, this prespecified analysis suggests that
ocriplasmin and VMA release are associated with visual benefit,
and that a data-driven, composite patient-reported outcome
may provide additional insight into the therapeutic effects of
ocriplasmin.
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